BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

743 related articles for article (PubMed ID: 27443619)

  • 1. The Prevalence and Clinical Features of Non-responsive Gastroesophageal Reflux Disease to Practical Proton Pump Inhibitor Dose in Korea: A Multicenter Study.
    Park HJ; Park SH; Shim KN; Kim YS; Kim HJ; Han JP; Kim YS; Bang BW; Kim GH; Baik GH; Kim HH; Park SY; Kim SS
    Korean J Gastroenterol; 2016 Jul; 68(1):16-22. PubMed ID: 27443619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they?
    de Bortoli N; Martinucci I; Savarino E; Bellini M; Bredenoord AJ; Franchi R; Bertani L; Furnari M; Savarino V; Blandizzi C; Marchi S
    Neurogastroenterol Motil; 2014 Jan; 26(1):28-35. PubMed ID: 23992024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors affecting response to proton pump inhibitor therapy in patients with gastroesophageal reflux disease: a multicenter prospective observational study.
    Matsuhashi N; Kudo M; Yoshida N; Murakami K; Kato M; Sanuki T; Oshio A; Joh T; Higuchi K; Haruma K; Nakada K
    J Gastroenterol; 2015 Dec; 50(12):1173-83. PubMed ID: 25851931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Algorithmic approach to patients presenting with heartburn and epigastric pain refractory to empiric proton pump inhibitor therapy.
    Roorda AK; Marcus SN; Triadafilopoulos G
    Dig Dis Sci; 2011 Oct; 56(10):2871-8. PubMed ID: 21512760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of the addition of prokinetics for proton pump inhibitor (PPI) resistant non-erosive reflux disease (NERD) patients: significance of frequency scale for the symptom of GERD (FSSG) on decision of treatment strategy.
    Miyamoto M; Manabe N; Haruma K
    Intern Med; 2010; 49(15):1469-76. PubMed ID: 20686276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic value of the PPI test for detection of GERD in Korean patients and factors associated with PPI responsiveness.
    Cho YK; Choi MG; Lim CH; Nam KW; Chang JH; Park JM; Lee IS; Kim SW; Choi KY; Chung IS
    Scand J Gastroenterol; 2010 May; 45(5):533-9. PubMed ID: 20180645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Demographic, clinical, and psychological characteristics of the heartburn groups classified using the Rome III criteria and factors associated with the responsiveness to proton pump inhibitors in the gastroesophageal reflux disease group.
    Lee KJ; Kwon HC; Cheong JY; Cho SW
    Digestion; 2009; 79(3):131-6. PubMed ID: 19307735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Underlying Mechanisms and Management of Refractory Gastroesophageal Reflux Disease].
    Lee KJ
    Korean J Gastroenterol; 2015 Aug; 66(2):70-4. PubMed ID: 26289239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical characteristics of gastroesophageal reflux diseases and association with Helicobacter pylori infection].
    Kim BC; Yoon YH; Jyung HS; Chung JB; Chon CY; Lee SI; Lee YC
    Korean J Gastroenterol; 2006 May; 47(5):363-9. PubMed ID: 16714878
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and clinical characteristics of refractoriness to optimal proton pump inhibitor therapy in non-erosive reflux disease.
    Ribolsi M; Cicala M; Zentilin P; Neri M; Mauro A; Efthymakis K; Petitti T; Savarino V; Penagini R
    Aliment Pharmacol Ther; 2018 Nov; 48(10):1074-1081. PubMed ID: 30294924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of treatment pattern and symptom control in patients with gastroesophageal reflux disease: multihospital questionnaire survey on the current situation in Korea.
    Seo SI; Bang CS; Kang HS; Choi MH; Shin WG; Jang HJ; Kim JB; Baik KH; Kae SH; Kim HY
    Dis Esophagus; 2017 Oct; 30(10):1-8. PubMed ID: 28859382
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prospective multicenter clinical and endoscopic follow-up study of patients with gastroesophageal reflux disease.
    Bajbouj M; Reichenberger J; Neu B; Prinz C; Schmid RM; Rösch T; Meining A
    Z Gastroenterol; 2005 Dec; 43(12):1303-7. PubMed ID: 16315125
    [TBL] [Abstract][Full Text] [Related]  

  • 13. More severe upper gastrointestinal symptoms associated with non-erosive reflux disease than with erosive gastroesophageal reflux disease during maintenance proton pump inhibitor therapy.
    Kusano M; Hosaka H; Kawamura O; Kawada A; Kuribayashi S; Shimoyama Y; Yasuoka H; Mizuide M; Tomizawa T; Sagawa T; Sato K; Yamada M
    J Gastroenterol; 2015 Mar; 50(3):298-304. PubMed ID: 24919745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigation of pretreatment prediction of proton pump inhibitor (PPI)-resistant patients with gastroesophageal reflux disease and the dose escalation challenge of PPIs-TORNADO study: a multicenter prospective study by the Acid-Related Symptom Research Group in Japan.
    Furuta T; Shimatani T; Sugimoto M; Ishihara S; Fujiwara Y; Kusano M; Koike T; Hongo M; Chiba T; Kinoshita Y;
    J Gastroenterol; 2011 Nov; 46(11):1273-83. PubMed ID: 21861141
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of risk factors and clinical responses to proton pump inhibitors in patients with erosive oesophagitis and non-erosive reflux disease.
    Lee ES; Kim N; Lee SH; Park YS; Kim JW; Jeong SH; Lee DH; Jung HC; Song IS
    Aliment Pharmacol Ther; 2009 Jul; 30(2):154-64. PubMed ID: 19392871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastroesophageal Reflux Disease-Related Disorders of Systemic Sclerosis Based on the Analysis of 66 Patients.
    Matsuda R; Yamamichi N; Shimamoto T; Sumida H; Takahashi Y; Minatsuki C; Kodashima S; Ono S; Niimi K; Tsuji Y; Sakaguchi Y; Saito I; Kataoka Y; Asada-Hirayama I; Kakimoto H; Yakabi S; Takeuchi C; Matsumoto Y; Tamaki Z; Fujishiro M; Asano Y; Sato S; Koike K
    Digestion; 2018; 98(4):201-208. PubMed ID: 30045036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Symptoms and quality of life in underweight gastroesophageal reflux disease patients and therapeutic responses to proton pump inhibitors.
    Hongo M; Miwa H; Kusano M;
    J Gastroenterol Hepatol; 2012 May; 27(5):913-8. PubMed ID: 22142515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The proton pump inhibitor test and the diagnosis of gastroesophageal reflux disease.
    Pace F; Pace M
    Expert Rev Gastroenterol Hepatol; 2010 Aug; 4(4):423-7. PubMed ID: 20678016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of gastroesophageal reflux disease in Korea and associated health-care utilization: a national population-based study.
    Kim KM; Cho YK; Bae SJ; Kim DS; Shim KN; Kim JH; Jung SW; Kim N
    J Gastroenterol Hepatol; 2012 Apr; 27(4):741-5. PubMed ID: 21916988
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics of refractory gastroesophageal reflux disease (GERD) symptoms -is switching proton pump inhibitors based on the patient's CYP2C19 genotype an effective management strategy?
    Takeuchi T; Oota K; Harada S; Edogawa S; Kojima Y; Sanomura M; Sakaguchi M; Hayashi K; Hongoh Y; Itabashi T; Kitae H; Hoshimoto M; Takeuchi N; Higuchi K
    Intern Med; 2015; 54(2):97-105. PubMed ID: 25742999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.